在治疗患有无形质症的儿童方面取得了进展
Tashunka Taylor-Miller1, Ravi Savarirayan1,2,3
1Victorian Clinical Genetics Service, Melbourne, Parkville, Victoria, Australia.
Expert review of endocrinology & metabolism
|August 12, 2024
概括
新的无骨质形成症治疗方法为患有这种骨疾病的儿童提供了希望. 批准的治疗方法,如vosoritide和新兴的精密药物,旨在改善生长并减少并发症.
科学领域:
- 骨发育不良症 骨发育不良症
- 儿科内分泌学 儿科内分泌学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨质疏松症是一种罕见的遗传骨疾病,在全球范围内影响了30万人.
- 从历史上看,阿德罗普拉西亚的治疗一直局限于症状管理.
- 最近的进展为受影响的儿童引入了有效的治疗选择.
研究的目的:
- 审查治疗治疗儿科无形质症的关键进展.
- 讨论已批准和正在研究的精密疗法.
- 总结这些新型治疗方法的当前临床试验结果.
主要方法:
- 目前关于无粒细胞形成症治疗方法的文献综述.
- 对vosoritide,navepegritide和infigratinib的临床试验数据的分析.
- 讨论新疗法对患者治疗结果的影响.
主要成果:
- 伏索里提德是首个被批准用于治疗无形质症的药物,标志着重要的治疗转变.
- 新兴疗法包括navepegritide和infigratinib,针对特定的途径.
- 这些治疗旨在改变生长轨迹并减少医学并发症.
结论:
- 沃索里提德的引入代表了阿德罗普拉西亚治疗的范式转变.
- 精密疗法有望改善生长,功能和减少并发症.
- 早期诊断和从出生开始获得向治疗对于最佳结果至关重要.
相关概念视频
Changes in the Appendicular Skeleton with Age
The upper and lower limb initially develops as a small bulge called a limb bud, which appears on the lateral side of the early embryo. The upper limb bud appears near the end of the fourth week of development, with the lower limb bud appearing shortly after.
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
Bone Formation by Endochondral Ossification
Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...
Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...


